2022 Urologic Cancer Course Overview
Since its inception in 1982, the multidisciplinary Urologic Cancer Course has been a biennial event that unites expertise from all Harvard teaching hospitals, alongside esteemed international specialists in urologic oncology, medical oncology, and radiation oncology. The course’s legacy of excellence has been shaped by leaders like Dr. Marc B. Garnick, Dr. Jerome P. Richie, Dr. Phillip W. Kantoff, and currently, Dr. Adam Kibel, Dr. Toni Choueiri, and Dr. Anthony V. D’Amico.
In 2022, we are honored to present keynote addresses by internationally renowned experts, Dr. George Daley, Dean of Harvard Medical School, and Dr. Lindsey Baden, Principal Investigator of the Covid Moderna Trial.
Who Should Attend?
- Primary Care Physicians
- Specialty Physicians
- Nurses and Nurse Practitioners
- Pharmacists
- Physician Assistants
- Psychologists
Learning Objectives
Participants will gain the ability to:
- Demonstrate optimal management of oligometastatic prostate, bladder, and renal cancer
- Explain the role of immunotherapy in managing bladder, prostate, and renal cancer
- Incorporate genomic classifiers, multiparametric MRI, and clinical parameters for selecting optimal patients with prostate cancer for active surveillance
Reviews
There are no reviews yet.